今年の「Drugs to Watch 2025」に含まれるリストは、160 人以上のクラリベイトのアナリストが、数百の疾患、医薬品および市場をカバーする専門知識を活用し、研究開発から商業化のライフサイクルまでの広い範囲を網羅する11の統合データセットを用いて特定したものです。
Drug Name | Company | Therapy Area | Year |
Budesonide | Calliditas Therapeutics AB | Primary immunoglobulin A (IgA) nephropathy/Berger's disease | 2024 |
Lovotibeglogene autotemcel | Bluebird Bio Inc. | Beta-thalassemia, Sickle cell disease | 2024 |
Aflibercept | Bayer AG, Regeneron Pharmaceuticals Inc. | Diabetic macular edema, Diabetic retinopathy, Wet age-related macular degeneration | 2024 |
Exagamglogene autotemcel | CRISPR Therapeutics, Vertex Pharmaceuticals Inc. | Beta-thalassemia, Sickle cell disease | 2024 |
Ensifentrine | Verona Pharma | COPD | 2024 |
Efanesoctocog alfa | Sanofi SA, Swedish Orphan Biovitrum AB | Hemophilia A | 2024 |
Datopotamab deruxtecan | AstraZeneca plc, Daiichi Sankyo Co. Ltd. | Breast cancer, NSCLC | 2024 |
Niraparib + abiraterone acetate | Johnson & Johnson | Prostate cancer | 2024 |
Donanemab | Eli Lilly and Co. | Alzheimer’s disease | 2022, 2023 |
Lecanemab | Biogen Inc., Esai Co Ltd. | Alzheimer’s disease | 2022, 2023 |
Foscarbidopa/foslevodopa | AbbVie Inc. | Parkinson’s disease | 2023 |
RSVpreF3 | GlaxoSmithKline plc | Respiratory syncytial virus (RSV) | 2024 |
Deucravacitinib | Bristol-Myers Squibb Co. | Plaque psoriasis | 2023 |
Daprodustat | GlaxoSmithKline plc | Chronic kidney disease (CKD)–related anemia | 2023 |
Capivasertib | AstraZeneca plc | Breast cancer | 2023 |
Bimekizumab | UCB | Plaque psoriasis | 2021, 2023 |
Faricimab | Roche and Chugai Pharmaceutical | Diabetic macular edema, Diabetic retinopathy, Wet age-related macular degeneration | 2022 |
Adagrasib | Mirati Therapeutics, Zai Lab Limited | KRASG12C-positive NSCLC and CRC | 2022 |
Tirzepatide | Eli Lilly and Co. | Type 2 diabetes mellitus (T2DM) | 2022 |
RSVpreF | Pfizer Inc. | Respiratory syncytial virus (RSV) | 2024 |
Tezepelumab | Amgen, AstraZeneca plc | Severe asthma | 2022 |
Talquetamab | Johnson & Johnson | Multiple myeloma | 2024 |
Relugolix | ASKA Pharmaceutical Co. Ltd., Gedeon Richter, Myovant Sciences Ltd, Pfizer Inc. | Endometriosis & uterine fibroids, Oncology, Prostate cancer, Reproductive health | 2021 |
Vericiguat | Bayer AG, Merck & Co. | Cardiovascular – heart failure | 2021 |
Zolbetuximab | Astellas Pharma Inc. | Gastric and gastroesophageal junction (GEJ) adenocarcinomas | 2024 |
Mirikizumab | Eli Lilly and Co. | Crohn’s disease and ulcerative colitis | 2023, 2024 |
Teclistamab | Janssen Pharmaceutical Companies of Johnson & Johnson | Multiple myeloma | 2023 |
Valoctocogene roxaparvovec | Biomarin Pharmaceutical Inc. | Hemophilia A | 2023 |
Teplizumab | Provention Bio Inc | Type 1 diabetes mellitus (T1DM) | 2023 |
Sparsentan | Travere Therapeutics Inc | Focal segmental glomerulosclerosis (FSGS), IgA nephropathy | 2023 |
Ritlecitinib | Pfizer Inc. | Alopecia areata | 2023 |
Pegcetacoplan | Apellis Pharmaceuticals Inc. | Geographic atrophy (GA), Paroxysmal nocturnal hemoglobinuria (PNH) | 2023 |
Lenacapavir | Gilead Sciences Inc. | HIV | 2023 |
Trastuzumab deruxtecan (DS-8201a; Enhertu) | AstraZeneca plc, Daiichi Sankyo Co. Ltd. | Oncology | 2020 |
Vadadustat | Akebia Therapeutics Inc., Mitsubishi Tanabe Pharma America Inc., Otsuka Pharmaceutical | Chronic disease complication | 2020 |
Valoctocogene roxaparvovec (BMN-270; Valrox) | Biomarin Pharmaceutical Inc. | Genetic disorder | 2020 |
Betibeglogene darolentivec (LentiGlobin) | Bluebird Bio Inc. | Genetic disorder | 2019 |
Onasemnogene abeparvovec (AVXS-101; Zolgensma) | AveXis | Genetic disorder | 2019 |
Palforzia (AR101; Aerumab) | Aimmune Therapeutics | Excessive immune response/autoimmunity | 2019 |
Ravulizumab (ALXN-1210; Ultomiris) | Alexion Pharmaceuticals Inc. | Excessive immune response/autoimmunity, Genetic disorder | 2019 |
Risankizumab (BI-655066; ABBV-066; Skyrizi) | AbbVie Inc., Boehringer Ingelheim | Excessive immune response/autoimmunity | 2019 |
Roxadustat (FG-4592; AZD-9941; ASP-1517; Ai Rui Zhuo) | Astellas Pharma Inc., AstraZeneca plc, FibroGen | Chronic disease complication | 2019 |
Upadacitinib (ABT-494; Rinvoq) | AbbVie Inc. | Excessive immune response/autoimmunity | 2019 |
Tenofovir alafenamide plus emtricitabine plus bictegravir (Biktarvy) | Gilead Sciences Inc. | Infectious disease | 2018 |
Avelumab (Bavencio) | Merck Serono, Pfizer Inc. | Oncology | 2017 |
Axicabtagene ciloleucel (KTE-C19; Yescarta) | Kite Pharma | Oncology | 2017 |
Baricitinib (Olumiant) | Eli Lilly and Co., Incyte Corp. | Excessive immune response/autoimmunity | 2017 |
Dupilumab (Dupixent) | Regeneron Pharmaceuticals Inc., Sanofi SA | Excessive immune response/autoimmunity | 2017 |
Durvalumab (Imfinzi) | AstraZeneca plc | Oncology | 2017 |
Niraparib (Zejula) | Tesaro | Oncology | 2017 |